When pharma’s R&D push peaked, hundreds of vaccines and treatments were in development to combat the novel coronavirus. And while the remobilization turned once-obscure biotechs like Moderna into ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $84.0, a ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Moderna (MRNA) with an Underperform rating and $40 price target Moderna may ...

While Pfizer already counts on oncology for boosting sales, Moderna’s sales are still made by the Covid shot, along with RSV ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Yes, you can get your flu and COVID-19 shots at the same time. Don't call them boosters — they're not just another dose of ...

The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...

Novavax has struggled to keep pace with rival vaccine makers Moderna and Pfizer ... including an experimental COVID-flu ...

The number of COVID cases increased last week to 146. Cases had been falling in April and May and were as low as 31 at the ...

The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...